Skip to content

Basket

You currently have no items in your basket.

Total (excl. vat) £0.00
View basket & checkout
Proteins and Peptides

Human Tumor Necrosis Factor Receptor Superfamily, Member 9 (TNFRSF9), Active Protein

Product Sizes
50 ug
£602.00
RPU54926-50UG
100 ug
£724.00
RPU54926-100UG
1 mg
£2865.00
RPU54926-1MG
About this Product
SKU:
RPU54926
Additional Names:
4-1BB|CD137|CDw137|ILA|Induced By Lymphocyte Activation|T-cell antigen 4-1BB homolog
Application:
Detection/Quantitation, Tissue Culture
Buffer:
Freeze-dried powder|PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
CE/IVD:
RUO
Extra Details:
Human Tumor Necrosis Factor Receptor Superfamily, Member 9 (TNFRSF9), Active Protein is a purified Prokaryotic Protein.
Formulation:
Freeze-dried powder
Immunogen:
Tumor Necrosis Factor Receptor Superfamily, Member 9 (TNFRSF9)
Molecular Weight:
16kDa
Physical State:
freeze-dried
Purity:
>97%
Shipping Conditions:
Blue Ice
Storage Conditions:
-20[o]C Avoid freeze/thaw cycles.
Supplier:
Biomatik
Type:
Proteins, Peptides, Small Molecules & Other Biomolecules: Recombinant Proteins
Catalog Protein.JPG
TNFRSF9 (Tumor necrosis factor receptor superfamily member 9) is a member of the TNF-receptor superfamily. This receptor contributes to the clonal expansion, survival, and development of T cells. A binding ELISA assay was conducted to detect the interaction of TNFRSF9 and TNFa. Briefly, recombinant human TNFRSF9 were diluted serially in PBS, with 0.01%BSA (pH 7.4). Duplicate samples of 100uL were then transferred to TNFa-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-TNFRSF9 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 3 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37°C. Finally, add 50uL stop solution to the wells and read at 450nm immediately. The binding activity of TNFRSF9 and TNFa was shown in Figure 1, and this effect was in a dose dependent manner.
Figure 2. SDS-PAGE